This Is Too Hot For Cidara Therapeutics Inc (NASDAQ: CDTX), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

As a NASDAQ listed company, CDTX falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Cidara Therapeutics Inc is $87.70M. A total of 1.74 million shares were traded on the day, compared to an average of 541.64K shares.

In the most recent transaction, Tari Leslie sold 21,029 shares of CDTX for 0.67 per share on Mar 11 ’24. After the transaction, the CHIEF SCIENTIFIC OFFICER now owns 258,681 company shares. In a previous transaction on Mar 11 ’24, Sandison Taylor sold 20,662 shares at 0.67 per share. CDTX shares that Chief Medical Officer owns now total 347,095.

Among the insiders who sold shares, Ward Shane disposed of 20,473 shares on Mar 11 ’24 at a per-share price of $0.67. This resulted in the COO & CLO holding 198,770 shares of CDTX after the transaction. In another insider transaction, Shah Preetam sold 18,931 shares at $0.67 per share on Mar 11 ’24. Company shares held by the CFO & CBO now total 227,210.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, CDTX has a high of $1.48 and a low of $0.59.

As of this writing, CDTX has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.07 per share and a lower estimate of -$0.16. The company reported an EPS of -$0.14 in the last quarter, which was -7.70% lower than expectations of -$0.13.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CDTX’s latest balance sheet shows that the firm has $59.68M in Cash & Short Term Investments as of fiscal 2021. There were $5.06M in debt and $34.02M in liabilities at the time. Its Book Value Per Share was $0.09, while its Total Shareholder’s Equity was $21.57M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CDTX is Buy with a score of 4.67.

Most Popular

Related Posts